Immuneering Corp.

As of August 10, 2022, Immuneering Corp. is considered overvalued with significant financial distress, reflected in its negative P/E ratio and other concerning metrics, despite a strong recent stock performance compared to the S&P 500.

As of June 20, 2025, Immuneering Corp. shows a mildly bearish trend due to daily moving averages and a bearish monthly RSI, despite a bullish weekly MACD and mixed signals from Bollinger Bands.

Immuneering Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $15 million and a market cap of $65.49 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -147.64%.

As of Jun 18, Immuneering Corp. has a market capitalization of 65.49 million and reported net sales of 0.00 million with a net profit of -61.78 million over the latest four quarters. Shareholder's funds are 41.39 million, and total assets are 52.71 million.